Please login to the form below

Not currently logged in
Email:
Password:

Boehringer Ingelheim to build $65m US research facility

Will add new R&D operations to its US headquarters in Connecticut

Boehringer Ingelheim is expanding its R&D operations in the US with a new research and development facility.

The $65m facility will be located at the company's US headquarters in Ridgefield, Connecticut and when completed will handle production of active pharmaceutical ingredients used in early development activities.

It brings the total of Boehringer's investment in the US this year to $350m, adding to spending on projects such as a $42m new drug safety assessment building in Ridgefield and a $50m high containment operations facility in Columbus, Ohio.

J Martin Carroll, president and CEO of the company's US operations, said: “These are exciting projects; ones that increase Boehringer Ingelheim's research and development capabilities and reinforce our commitment to growth and innovation in the US.”

“Through these investments we are improving our ability to research, develop and manufacture the medicines of tomorrow and in doing so fulfilling our promise to bring more health to patients and their families.”

15th November 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics